Mass General, Harvard to Use Illumina Genotyping Tech in Large ALS Study | GenomeWeb
NEW YORK (GenomeWeb News) – Illumina today said researchers from Massachusetts General Hospital and Harvard Medical School will use data from its Sentrix HumanHap300 BeadChips and Infinium assay reagents to run a whole-genome association study of amyotrophic lateral sclerosis.
 
The 2,200-sample case/control study is the largest genetic study to date of ALS, according to study co-supervisor Adrian Ivinson, director of Harvard’s Center for Neurodegeneration and Repair.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.